Zimmer Biomet Holdings Inc. (ZBH) shares plunged over 5% in the pre-market trading session on Thursday, despite reporting better-than-expected Q4 2024 earnings. The medical device maker's disappointing full-year 2025 profit forecast overshadowed its quarterly results.
For Q4 2024, Zimmer Biomet reported adjusted earnings of $2.31 per share, narrowly beating analysts' expectations of $2.30. Revenue of $2.02 billion also edged past estimates of $2.01 billion, driven by strong demand for its hip and knee implants as well as sports medicine and trauma care products.
However, the company's full-year 2025 adjusted profit guidance of $8.15 to $8.35 per share fell short of Wall Street's consensus estimate of $8.56. Zimmer Biomet expects a 1.5% to 2% negative impact on revenue due to a stronger U.S. dollar. Additionally, its recent acquisition of orthopedic surgical device maker Paragon 28 is expected to weigh on earnings by around 10 cents per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.